A5080075892- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune cells in cancer
- Hematological disorders and diagnostics
- Single-cell and spatial transcriptomics
- Digital Imaging for Blood Diseases
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Blood groups and transfusion
- Toxin Mechanisms and Immunotoxins
- Chromatin Remodeling and Cancer
- Blood disorders and treatments
- Neutropenia and Cancer Infections
- Erythrocyte Function and Pathophysiology
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Microfluidic and Bio-sensing Technologies
- Clinical Laboratory Practices and Quality Control
- Eosinophilic Disorders and Syndromes
- Bone and Joint Diseases
- Inflammatory Biomarkers in Disease Prognosis
- Fungal Infections and Studies
- Chemokine receptors and signaling
- Platelet Disorders and Treatments
Hôpitaux Universitaires Henri-Mondor
2015-2024
Assistance Publique – Hôpitaux de Paris
2018-2024
Université Paris-Est Créteil
2022-2023
Université Gustave Eiffel
2023
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed nationwide network to collect data from new cases diagnosed in France. In retrospective, observational study of 86 patients (2000-2013), described clinical biological focusing on morphologies immunophenotype. We found expression markers associated with origin (HLA-DRhigh, CD303+, CD304+, cTCL1+) plus CD4 CD56 frequent isolated the myeloid, B-, T-lymphoid lineages, whereas...
BackgroundAcute leukaemias are life-threatening haematological cancers characterised by the infiltration of transformed immature haematopoietic cells in blood and bone marrow. Prompt accurate diagnosis three main acute leukaemia subtypes (ie lymphocytic [ALL], myeloid [AML], promyelocytic [APL]) is utmost importance to guide initial treatment prevent early mortality but requires cytological expertise that not always available. We aimed benchmark different machine-learning strategies using a...
Although numerous recent publications have demonstrated interest in multiparameter flow cytometry the investigation of myelodysplastic disorders, it is perceived by many laboratory hematologists as difficult and expensive, requiring a high level expertise. We report multicentric open real-life study aimed at evaluating added value technically simple score described Ogata group for diagnosis syndromes. A total 652 patients were recruited prospectively four different centers: 346 syndromes, 53...
Accumulation of classical monocytes CD14++ CD16- (also called MO1) ≥ 94% can accurately distinguish chronic myelomonocytic leukemia (CMML) from reactive monocytosis. The HematoFlow™ solution, able to quantify CD16 negative monocytes, could be a useful tool manage monocytosis which remains common issue in routine laboratories.Classical were quantified 153 whole blood samples collected on EDTA using both flow cytometry methods, either MO1 percentage determination by the multiparameter assay...
WBC differentials performed using flow cytometry with monoclonal antibodies have been developed in the last decade and are nowadays integrated into routine workflow of some laboratories. Definition reference values for each population is required order to achieve an automatic validation results by laboratory software. We analyzed 584 samples from three hospitals Hematoflow solution define values. Reference presented five groups according age (0-5, 6-11, 12-19, 20-69, >69 years). These normal...